

Lung cancer: Peer-reviewed journal articles featuring Fortrea oncologists



The revolution in lung cancer therapies has its foundation in understanding the biology of cancer. Whether biomarker protein expression or genomic alterations, Fortrea SMEs such as Dr. Luca Cantini understand this space, helping you bring the right treatment to the right lung cancer patient faster.

Fortrea supports our sponsors with a team of 50+ oncologists who employ a collaborative approach, which can result in co-authorship of peer-reviewed journal articles based on projects we've supported. In addition, they have contributed to industry knowledge via articles about their own academic and collaborative work.

2025	
Number	Authors, Title, Journal
2025.1	<p>Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Jayakrishnan R, et al. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\geq50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. <i>BMJ Journals</i>. February 2025.</p> <p>https://doi.org/10.1136/jitc-2024-010674</p> <p>Summary: This paper analyzes the determinants of 5-year survival in patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression \geq50%, treated with first-line pembrolizumab outside of clinical trials. Using data from the Pembro-real 5Y global registry, the study identifies key factors influencing long-term outcomes, such as patient characteristics, tumor biology, and treatment patterns. The findings provide valuable insights into real-world applications of pembrolizumab, highlighting its potential to improve survival in this patient population while addressing challenges like variability in response and resistance mechanisms.</p>
2024	
Number	Authors, Title, Journal
2024.1	<p>Strickland KC, Nesline MK, Previs RA, Ko H, Wallen ZD, Pabla S, Conroy JM, Sausen M, Saini KS, Cantini L, Jensen T, Caveney BJ, Eisenberg M, Severson EA, Ramkissoon SH. Single Gene Testing and Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer: A Case Series of Divergent Results from a Large Reference Laboratory. <i>Frontiers in Oncology</i>. October 2024.</p> <p>https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1445668/full</p> <p>Summary: This paper presents a case series comparing single-gene testing (SGT) and comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC). It highlights the limitations of SGT, which may miss actionable genetic alterations due to its narrower scope, and contrasts it with CGP, which uses next-generation sequencing to provide a broader molecular profile. The authors discuss four cases where CGP identified actionable alterations that SGT did not, emphasizing the importance of CGP in guiding personalized treatment and clinical trial opportunities. The study underscores the value of CGP in precision oncology, while addressing challenges like cost and tissue availability.</p>



See a full list of Fortrea oncology publications starting in 2020.

 **LEARN MORE** at fortrea.com